ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
INTRODUCTION
Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid‐related imaging abnormalities (ARIA) profiles appear to differ for various anti‐amyloid antibodies. Here, we present ARIA data from a large phase 2 l...
Alternative Titles
Full title
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3cf542a8e09a48118eb52ac3667c50a8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3cf542a8e09a48118eb52ac3667c50a8
Other Identifiers
ISSN
2352-8737
E-ISSN
2352-8737
DOI
10.1002/trc2.12377
